CIMAVAX-EGF VACCINE IN A PATIENT WITH ADVANCED STAGE LUNG CANCER

https://doi.org/10.56274/rcs.2024.3.2.43

Abstract

Introduction: Therapeutic vaccination for the treatment of cancer depends on the induction of a specific immune response against tumor-associated antigens and is currently considered one of the most promising strategies for the therapy of this disease. Objective: To describe the experience of using the Cimavax-EGF vaccine in a patient with lung cancer in advanced stages. Clinical case: 62-year-old, male patient, with health history, smoker for 40 years. I started studies at another health center for evaluation due to frequent coughing, without other associated symptoms. Conclusions: In the case studied, the safety of the Cimavax-EGF vaccine was demonstrated. Our patient had a survival superior to that reported in the literature.